Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms.

[1]  É. Oksenhendler,et al.  Common variable immunodeficiency is associated with defective functions of dendritic cells. , 2004, Blood.

[2]  S. Varambally,et al.  Natural antibodies sustain differentiation and maturation of human dendritic cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[3]  R. Steinman,et al.  Immunotherapy: Bewitched, Bothered, and Bewildered No More , 2004, Science.

[4]  M. Dalakas,et al.  Intravenous immunoglobulin in autoimmune neuromuscular diseases. , 2004, JAMA.

[5]  S. Kaveri,et al.  Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era? , 2004, Trends in Pharmacological Sciences.

[6]  S. Kaveri,et al.  Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus. , 2003, Arthritis and rheumatism.

[7]  H. Simon,et al.  Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. , 2003, The Journal of allergy and clinical immunology.

[8]  K. Siminovitch,et al.  IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity. , 2003, Blood.

[9]  K. Bhol,et al.  Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris. , 2003, European journal of dermatology : EJD.

[10]  Eric M. Billings,et al.  F(ab)′2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins , 2003, Nature Medicine.

[11]  R. Geha,et al.  IgG Fc receptor polymorphisms in human disease: implications for intravenous immunoglobulin therapy. , 2003, The Journal of allergy and clinical immunology.

[12]  S. Kaveri,et al.  Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. , 2003, Blood.

[13]  W. Sewell,et al.  Immunomodulatory action of intravenous immunoglobulin , 2002, Immunology.

[14]  A. Ahmed,et al.  Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus. , 2002, Clinical immunology.

[15]  S. Kaveri,et al.  Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. , 2001, The New England journal of medicine.

[16]  S. Kumari,et al.  Pemphigus vulgaris: the role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production. , 2001, Clinical immunology.

[17]  S. Kaveri,et al.  Antibodies to C-C Chemokine Receptor 5 in Normal Human IgG Block Infection of Macrophages and Lymphocytes with Primary R5-Tropic Strains of HIV-11 , 2001, The Journal of Immunology.

[18]  J. Ravetch,et al.  Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. , 2001, Science.

[19]  S. Kaveri,et al.  Phosphorylation of Bcl-2 and mitochondrial changes are associated with apoptosis of lymphoblastoid cells induced by normal immunoglobulin G. , 1999, Biochemical and biophysical research communications.

[20]  H. Chapel.  Safety and availability of immunoglobulin replacement therapy in relation to potentially transmissable agents , 1999, Clinical and experimental immunology.

[21]  M. Swash,et al.  IV immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome , 1999, Neurology.

[22]  S. Kaveri,et al.  Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). , 1999, Blood.

[23]  V. Lennon,et al.  Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. , 1999, The New England journal of medicine.

[24]  J. Tschopp,et al.  Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. , 1998, Science.

[25]  S. Kaveri,et al.  Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. , 1998, Journal of immunology.

[26]  Fontana,et al.  High‐Dose Intravenous Immunoglobulin Treatment Activates Complement In Vivo , 1998, Scandinavian journal of immunology.

[27]  K. Bendtzen,et al.  High-avidity autoantibodies to cytokines. , 1998, Immunology today.

[28]  K. Bendtzen,et al.  Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. , 1998, Blood.

[29]  H. Hartung,et al.  Side effects of high-dose intravenous immunoglobulins. , 1997, Clinical neuropharmacology.

[30]  M. Ballow.  Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. , 1997, The Journal of allergy and clinical immunology.

[31]  A. Brand,et al.  The Growth Arresting Effect of Human Immunoglobulin for Intravenous Use Is Mediated by Antibodies Recognizing Membrane Glycolipids , 1997, Journal of Clinical Immunology.

[32]  M. Dalakas.  Intravenous Immune Globulin Therapy for Neurologic Diseases , 1997, Annals of Internal Medicine.

[33]  E. Gelfand,et al.  Posttranscriptional regulation of T-cell IL-2 production by human pooled immunoglobin. , 1997, Clinical immunology and immunopathology.

[34]  E. Gelfand,et al.  Intravenous immune globulin: an alternative therapy in steroid‐dependent allergic diseases , 1996, Clinical and experimental immunology.

[35]  U. Andersson,et al.  Intravenous immune globulin affects cytokine production in T lymphocytes and monocytesjmacrophages , 1996, Clinical and experimental immunology.

[36]  S. Kaveri,et al.  Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. , 1996, The Journal of clinical investigation.

[37]  M. E. Ryan,et al.  Averse Effects of Intravenous Immunoglobulin Therapy , 1996, Clinical pediatrics.

[38]  J. Cavaillon,et al.  Selective induction of interleukin‐1 receptor antagonist and interleukin‐8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin) , 1995, European journal of immunology.

[39]  M. Dalakas,et al.  High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. , 1994, The Journal of clinical investigation.

[40]  D. Klatzmann,et al.  Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg). , 1994, Therapeutic immunology.

[41]  U. Andersson,et al.  Pooled Human IgG Modulates Cytokine Production in Lymphocytes and Monocytes , 1994, Immunological reviews.

[42]  D. Tankersley.  Dimer Formation in Immunoglobulin Preparations and Speculations on the Mechanism of Action of Intravenous Immune Globulin in Autoimmune Diseases , 1994, Immunological reviews.

[43]  S. Kaveri,et al.  V Region‐Mediated Selection of Autoreactive Repertoires by Intravenous Immunoglobulin (i.v.Ig) , 1994, Immunological reviews.

[44]  J. Mcnicholl,et al.  Immunologically active proteins in intravenous immunoglobulin , 1993, The Lancet.

[45]  U. Andersson,et al.  Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. , 1993, Immunology.

[46]  M. Kazatchkine,et al.  Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg) , 1993, Clinical and experimental immunology.

[47]  R. Blasczyk,et al.  Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations , 1993, The Lancet.

[48]  I. Lundkvist,et al.  Polyvalent immunoglobulin for intravenous use interferes with cell proliferationin vitro , 1992, Journal of Clinical Immunology.

[49]  J. Marchalonis,et al.  Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[50]  R. Liblau,et al.  Intravenous γ-globulin in myasthenia gravis: Interaction with anti-acetylcholine receptor autoantibodies , 1991, Journal of Clinical Immunology.

[51]  M. Frank,et al.  High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes , 1991 .